Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Selumetinib in Combination with Anti Retroviral Therapy in HIV-associated Kaposi sarcoma (SCART): an open-label, multicentre, phase I/II trial

Fig. 3

Best clinical response. Waterfall plot showing best clinical response recorded during the planned 6 treatment cycles in the any-dose/safety population. Fourteen of 16 patients are shown; two were omitted from this plot due to incomplete measurements; one with reported stable disease, one with progressive disease. Note two patients, both marked with *, one with stable disease and one with partial response in target lesions are marked as progressive disease as per ACTG criteria due to an increase in (off-target) lesion number. Overall, 1/16 partial response, 11/16 stable disease, 3/16 progressive disease as best response

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us